Acublate Overview
- Year Founded
-
2010

- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Acublate General Information
Description
Provider of therapeutic services designed to offer novel ultrasound device for the treatment of cancer. The company's therapeutic services include development of devices that use phased array technology consisting of transducers, resulting in focused beams that can be steered in three-dimensional imaging, providing consumers with ultrasound surgery devices to treat and melt cancer tumors.
Contact Information
Corporate Office
- Angel Building
- 407 Saint John Street
- London EC1V 4AD
- England, United Kingdom
Corporate Office
- Angel Building
- 407 Saint John Street
- London EC1V 4AD
- England, United Kingdom
Acublate Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 05-Feb-2019 | Completed | Out of Business | |||
1. Early Stage VC | 27-Jan-2012 | Completed | Startup |
Acublate Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary |
Acublate FAQs
-
When was Acublate founded?
Acublate was founded in 2010.
-
Where is Acublate headquartered?
Acublate is headquartered in London, United Kingdom.
-
What industry is Acublate in?
Acublate’s primary industry is Therapeutic Devices.
-
Is Acublate a private or public company?
Acublate is a Private company.
-
What is Acublate’s current revenue?
The current revenue for Acublate is
. -
How much funding has Acublate raised over time?
Acublate has raised $224K.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »